Nycomed seeks bidders for potential $13B sale

Swiss drugmaker Nycomed has hired Goldman Sachs to scout for buyers up for a $13.5 billion deal. Options include licensing Nycomed's experimental lung-disease drug, an IPO, or an outright sale of the entire company. The drugmaker's large business in Eastern Europe and Russia could make it attractive to Big Pharmas looking to grow in emerging markets. Report | Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.